New research from Washington State University in collaboration with five other institutions suggests that automated insulin ...

New research suggests that automated insulin delivery (AID) systems are safe and effective for use by older adults with type 1 diabetes. The findings counter common assumptions that older adults would ...

manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare ...

ViCentra announced today that it appointed Tom Arnold as its new CEO to accelerate growth with the Kaleido automated insulin ...

Tandem is following competitor Insulet’s lead with the second automated insulin delivery system indicated for Type 2 diabetes.

Embecta's compelling ~44% free cash flow yield offers a strong risk-reward despite headwinds from new insulin technologies ...

Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.

Arti Masturzo, M.D., chief medical officer of CCS, spoke with MHE in this third part of a video series to share how CCS helps ...

Tandem Diabetes Care (Nasdaq:TNDM) shares took a hit after hours today on fourth-quarter results that topped the consensus ...

Tandem Diabetes Care, Inc. reported strong Q4 2024 earnings, but shares declined 30%. Click for my TNDM stock update in light ...

Tandem Diabetes Care, Inc.’s TNDM fourth-quarter 2024 performance was driven by its impressive range of new products. The company’s impressive strategic initiatives provide a favorable opportunity for ...